**Core tip:** While data regarding the role of per-oral endoscopic pyloromyotomy (G-POEM) for the treatment of gastroparesis are still emerging, it is a promising technique that may significantly benefit specific gastroparesis subtypes with functional gastric outlet obstruction. More data are needed, however, to determine exactly where G-POEM falls in the armamentarium of gastroparesis treatment strategies.

INTRODUCTION
============

Gastroparesis, characterized by the symptom constellation of early satiety, nausea, vomiting, bloating, postprandial fullness, and upper abdominal pain in the presence of delayed gastric emptying, is an increasingly recognized cause of significant foregut morbidity. Initially thought to be an uncommon disease entity, gastroparesis has experienced a marked increase in prevalence over the past decade; with a growing number of reports indicating increasing emergency room visitations, hospitalizations and health care utilization\[[@B1]-[@B4]\].

Gastroparesis is a heterogeneous condition most commonly idiopathic in nature, but also frequently identified in diabetes, connective tissues disease, neurologic disorders, and as a complication of intrathoracic or intrabdominal procedures\[[@B5],[@B6]\]. Numerous underlying pathophysiologic mechanisms have been proposed, but the true pathophysiology of gastroparesis is not well elucidated\[[@B5],[@B6]\]. Because of this limitation, the medical treatment for gastroparesis is largely empiric with the goal of increasing upper gastrointestinal (GI) motility and providing supportive symptomatic relief\[[@B5]-[@B8]\]. The only medication that is approved by the Food and Drug Administration for the treatment of gastroparesis at present is metoclopramide; although other agents are frequently used off label. Other medical treatments for gastroparesis includes the use of prokinetic agents such as dopaminergic antagonists like domperidone, utilizing the antibiotic erythromycin's effects on motilin receptors in the gut to stimulate gastric motility, employment of anti-emetics, or use of neuromodulators\[[@B5]-[@B9]\]. Unfortunately, the efficacy of these agents has been limited by the presence of tachyphylaxis, or significant cardiovascular or neurologic side effect profiles that restrict the ability to continue these medical therapies long term\[[@B5]-[@B9]\].

In 1986, Mearin *et al*\[[@B10]\] published a landmark paper that demonstrated abnormally prolonged, high-amplitude pyloric contractions within a subset of patients with gastroparesis. Since that publication, suspected "pylorospasm", has been the target of a multitude of surgical and endoscopic therapies. These therapies include pyloric injection of botulinum toxin, endoscopic dilatation, placement of trans-pyloric stents, and surgical pyloroplasty or pyloric myotomy\[[@B11]-[@B18]\]. However, widespread application of these modalities has been dampened by either the invasiveness of the procedure or a failure to demonstrate consistent long-term efficacy\[[@B5],[@B6],[@B11]-[@B18]\]. However, recent advances in endoscopic submucosal dissection have led to the development of novel endoscopic tunneling techniques that have been associated with significant therapeutic potential. Pasricha *et al*\[[@B19]\] in 2007 incorporated these submucosal tunneling techniques along with an endoscopic myotomy in pigs for treatment of achalasia and subsequently Inoue *et al*\[[@B20]\] in 2010 first reported the initial clinical experience of these techniques in humans. Since publication of these experiences, these techniques have been increasingly applied to good effect for the treatment of functional esophageal disease\[[@B21],[@B22]\]. Utilizing this successful model as a template, the technical feasibility of per-oral endoscopic pyloromyotomy (G-POEM or POP) was initially described in 2012 by Kawai *et al*\[[@B23]\] in a porcine model. Following this publication, the first successful G-POEM in humans was described by Khashab *et al*\[[@B24]\] in 2013. This report details a patient with refractory debilitating gastroparesis who underwent a successful endoscopic pyloromyotomy with marked improvement in symptoms 12 weeks following the procedure\[[@B24]\]. After this initial report, over a dozen published reports of successful G-POEM procedures have been identified in the English literature indicating that we have now entered an era of increased utilization of per-oral endoscopic myotomy for the treatment of gastroparesis\[[@B25]-[@B34]\]. The aim of this article is to review the technical aspects of the G-POEM procedure for the treatment of gastroparesis, provide an overview of the currently published literature, and outline potential next directions for the field.

TECHNICAL ASPECTS OF THE PER-ORAL ENDOSCOPIC PYLOROMYOTOMY PROCEDURE
====================================================================

In our experience, G-POEM for the treatment of gastroparesis is divided into 5 stages: (1) The initial endoscopic inspection; (2) Initial mucosotomy; (3) Submucosal tunnel formation; (4) Pyloric myotomy; and (5) Mucosal Closure (Figure [1](#F1){ref-type="fig"}).

![Per-oral endoscopic pyloromyotomy procedure in 5 steps. A: Initial inspection; B and C: Mucosotomy; D: Submucusal tunnel dissection with identification of pyloric ring; E: Pyloromyotomy; F: Mucosal closure.](WJG-25-2581-g001){#F1}

Step 1: Initial endoscopic inspection
-------------------------------------

In stage 1, the initial endoscopic inspection is performed to clear the surgical field of food or residual debris and to identify any contraindications such as mass or ulceration which would preclude continuation of the procedure. At our institution, we commonly assess pyloric distensibility utilizing a 325/8 cm sized endoscopic Functional Lumen Imaging Probe (FLIP, EndoFlip, Medtronic, Sunnyvale, California) during this step (Figure [1A](#F1){ref-type="fig"}).

Step 2: Mucosotomy
------------------

The submucosa is injected with 4-6 mL of lifting solution \[0.25% indigo carmine into 500 mL HESPAN (6% Hetastarch in 0.9% Sodium Chloride solution)\] 4-5 cm proximal to the pyloric channel along the greater curvature of the stomach. We utilize a triangle tip (TT) endoscopic knife (KD640L, Olympus, Tokyo, Japan) using EndoCut Q setting at 50 W, effect 2 (VIO300D, ERBE, Tϋbingen, Germany) to create a 1-1.5 cm transverse mucosal incision above the submucosal injection (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}).

Step 3: Submucosal tunnel formation
-----------------------------------

Upon creation of the mucosotomy, the endoscope is advanced into the submucosal space. Submucosal dissection is performed using either the TT or IT-nano (KD 604L or KD 612L, Olympus, Tokyo, Japan) endoscopic knifes, based on anatomic orientation. The submucosal fibers are dissected using spray coagulation mode (50-80 W, effect 2) or forced coagulation mode (50-80 W, effect 2). The submucosal tunnel is extended until the pyloric ring is visualized (Figure [1D](#F1){ref-type="fig"}). Frequent orientation by exiting the tunnel and visualizing the pylorus is performed throughout creation of the submucosal tunnel to ensure appropriate directionality. Lifting solution is intermittently applied *via* a spray catheter to aid visualization of the submucosal plane and better demarcate the mucosa and submucosal layers. Any obstructing submucosal vessels are cauterized using coagulation graspers (FD 410 LR, Olympus, Tokyo, Japan) in soft coagulation mode (80 W, effect 3).

Step 4: Myotomy
---------------

Upon visualization of the pyloric ring, a full thickness pyloromyotomy down to the serosal layer is performed using either the TT or IT-nano endoscopic knifes with an EndoCut Q current (50 W, effect 2). The myotomy is extended approximately 1-2 cm proximal to the pyloric ring to ensure that the pyloric sphincter has been completely cut (Figure [1D](#F1){ref-type="fig"} and [E](#F1){ref-type="fig"}).

Step 5: Closure
---------------

The mucosal defect is then closed with endoscopic sutures using the OverStitch™ Endoscopic Suturing System (Apollo Endosurgery Inc, Austin, Texas) (Figure [1E](#F1){ref-type="fig"}). In our practice all patients with medically refractory gastroparesis or with symptom severity sufficient to justify endoscopic intervention are considered for the procedure. Nausea and vomiting are subjectively the symptoms we feel most respond to intervention and we focus on people with these symptoms specifically, rather than those that present primarily with pain. Our practice is to perform a baseline gastric emptying, symptom assessment and assessment of pyloric distensibility (FLIP) prior to (or during) the G-POEM procedure.

Patients are kept *nil per os* the night before the procedure. If there is a history of gastric food remnant in the stomach, a longer period of a liquid diet is employed to ensure that the stomach is empty for the procedure. Anesthesia is employed to ensure that the patient is kept motionless during the procedure.

Following the procedure, the patient is admitted to the hospital for post procedural observation, initiated on post procedural IV antibiotics and keep on gut rest until a follow up upper GI gastrografin study is obtained the following morning. If no extraluminal contrast is identified the patient's diet is advanced to a full liquid diet, and the patient is discharged on 5 d of oral antibiotic therapy and acid suppression *via* twice daily proton pump for 4-8 wk. Our average length of hospitalization is 1-2 d. Repeat gastric emptying, pyloric distensibility and symptom assessment is typically obtained 12 wk post procedure.

CURRENT DATA
============

Table [1](#T1){ref-type="table"}\[[@B25]-[@B34]\] depicts the preclinical, procedural and post-procedural outcomes in the largest reported G-POEM or POP reports published to date. When the data are aggregated, a total of 325 patients underwent the G-POEM procedure with 100% noting technical success. Major complications were noted in 8.3% of all patients noted, the most common of which were capnomediastinum or capnoperitoneum followed by antral or prepyloric ulceration and GI bleeding. Only 3 perforations were reported, and all healed with supportive care. The mean length of stay ranged from 1-5 d with a mean procedural length ranging from 37-120 min. Rodriguez *et al*\[[@B29]\] noted decreased procedural times with increased familiarity with the procedure. The majority of patients were female in their 5^th^ to 6^th^ decade of life and the etiology of gastroparesis was noted to be idiopathic in 45%, diabetic in 28%, and post-surgical in 22%. Other than medical therapy, a wide range of previous treatments for gastroparesis were reported with botulinum toxin and gastric stimulator placement being the two most commonly reported.

###### 

Depicts pre-clinical demographic and clinical data and post-operative changes to symptoms and gastric emptying

  **Article**                                  **Shlomovitz et al\[[@B25]\], 2014**   **Gonzalez et al\[[@B26]\], 2017**   **Kahaleh et al\[[@B27]\], 2018**                      **Rodriguez et al\[[@B28]\], 2017**   **Rodriguez et al\[[@B29]\], 2018**    **Malik et al\[[@B30]\], 2018**   **Jacques et al\[[@B31]\], 2017**   **Dacha et al\[[@B32]\], 2017**   **Mekaroonkamol et al\[[@B33]\], 2018**            **Khashab et al\[[@B34]\], 2017**
  -------------------------------------------- -------------------------------------- ------------------------------------ ------------------------------------------------------ ------------------------------------- -------------------------------------- --------------------------------- ----------------------------------- --------------------------------- -------------------------------------------------- -----------------------------------
  *n*                                          7                                      29                                   33                                                     47                                    100                                    13                                20                                  16                                30                                                 30
  Female (%)                                   100                                    65.50                                66                                                     78.70                                 85.00                                  53.58                             ---                                 81.25                             86.70                                              57
  Age (mean)                                   51                                     52.8                                 52                                                     43.7                                  45                                     45.7                              ---                                 44.76                             47                                                 47
  Previous gastric stim                        ---                                    4 (13.8%)                            2 (6%)                                                 16 (34.0%)                            20 (20%)                               3 (23%)                           0                                   4 (25%)                           4 (13.3%)                                          0
  Previous botox treatment                     ---                                    1 (3%)                               4 (12%)                                                28 (59.6%)                            46 (46%)                               11 (84.6%)                        2 (10%)                             0                                 1 (3%)                                             12 (40%)
  Pre GES 4 h (mean %)                         21                                     40 ± 34                              45                                                     37.2 ± 25.1                           39 ± 26.5                              49 ± 24                           57                                  62.5                              63.0 ± 25.5                                        37
  Pre GCSI                                                                            3.3 ± 0.9                                                                                   4.61                                  3.8 ± 0.86                             2.2 ± 0.8                         3.5                                 3.41                              3.5 ± 0.6                                          
  Gastroparesis: Idiopathic                    4                                      15                                   12                                                     27                                    56                                     4                                 4                                   5                                 12                                                 7
  Gastroparesis: Diabetes                      0                                      7                                    7                                                      12                                    21                                     1                                 10                                  9                                 12                                                 11
  Gastroparesis: Post-surgical                 2                                      5                                    12                                                     8                                     19                                     8                                 1                                   1                                 5                                                  12
  Gastroparesis: Scleroderma                   0                                      2                                    2                                                      ---                                   ---                                    ---                               1                                   0                                 0                                                  0
  Total of major postoperative complications   4/7                                    5/29                                 1/33                                                   0/47                                  10/100                                 1/13                              3/20                                0/16                              1                                                  2/30
  Post GES Residual 4 hours                    4%                                     28 ± 45                              17% ± 17                                               20.4 ± 26.1                           16.3 ± 21.4                            33 ± 28                           15                                  25.4                              22.2 ± 20.5                                        17% ± 16
  Symptom improvement                          85.70%                                 69%                                  86%                                                    ---                                   ---                                    73%                               90%                                 81%                               76.70%                                             86%
  How defined improvement                      Clinical improvement                   Decrease in GCSI                     Clinical improvement[1](#T1FN1){ref-type="table-fn"}   Not defined                           Not defined                            CPGAS score                       GCSI decrease by 0.75               Decrease in GCSI                  Decrease in GCSI[2](#T1FN2){ref-type="table-fn"}   Clinical improvement
  Length of follow up (mo)                     6.5                                    6                                    6                                                      3                                     3                                      3                                 3                                   12                                6-18                                               6
  Timing of F/u GES in days                    84                                     56                                   ---                                                    90                                    90                                     84                                84                                  56                                42-56                                              81-105
  GES improvement                              4/5 (90%)                              23/29 (79.3%)                        ---                                                    ---                                   78% [α](#T1FN3){ref-type="table-fn"}   4/6 (66.7%)                       19/20 (95%)                         12/12 (100%)                      78.3%[α](#T1FN3){ref-type="table-fn"}              14/17, 82.3%
  Normalization of GES                         0/5                                    16/29                                4/6                                                    ---                                   57% [α](#T1FN3){ref-type="table-fn"}   0                                 6/20                                9/12                              47.8%[α](#T1FN3){ref-type="table-fn"}              8/17

And lack of hospitalizations;

Defined as 1 averaged point in total Gastroparesis Cardinal Symptom Index with more than 25% decrease in 2 subscales;

Total number not provided. GCSI: Gastroparesis Cardinal Symptom Index; GES: Gastric Emptying Study; CPGAS: Clinical Patient Grading Assessment Scale.

Clinical success was noted in 68%-90% of patients. 3 studies defined clinical success as any symptomatic improvement\[[@B25],[@B27],[@B34]\], with 4 studies identifying any decrease in Gastroparesis Cardinal Symptom Index (GCSI) or Clinical Patient Grading Assessment Scale score as clinical success\[[@B26],[@B30],[@B32],[@B33]\]. Only one study utilized an absolute GCSI decrease (0.75 points) as a marker for success\[[@B31]\]. Two studies did not define parameters for clinical success\[[@B28],[@B29]\]. An improvement in gastric emptying scores at 4 hours was reported in 67%-90% of all patients with follow up Gastric Emptying Study (GES) studies. Normalization of the GES at 4 h was noted in 0-66% of all gastric emptying studies, although significant drop out rates were reported. Eight studies reported follow up intervals of less than 7 mo.

No clinical parameters were identified that reliably predicted G-POEM success. Gonzalez et al\[[@B26]\] noted that female gender and diabetes were associated with a higher rate of failure in a univariant analysis; however, these results were not corroborated in a multivariate analysis. Malik *et al*\[[@B30]\] and Jacques *et al*\[[@B31]\] were the only authors to study the pre- and post-pyloric distensibility with FLIP. While Malik *et al*\[[@B30]\] identified a larger cross sectional area at 40 mL balloon in those that improved with G-POEM, Jacques et al\[[@B31]\] identified that at 50 ml a Distensibility Index of \< 9.2 mm^2^/mmHg was 100% specific and 72.2% sensitive with regards to clinical efficacy of G-POEM. No other parameters were identified that predicted success or failure of the G-POEM procedure. Table [2](#T2){ref-type="table"} depicts the procedural variability across the studies. Note the large variation between studies in regard to the site of mucosotomy, endoscopic equipment used, and post-operative testing and care including antibiotics and acid suppression.

###### 

Demonstrates procedural data including equipment used and post-operative practice reported across the studies

  **Article**                                   **Shlomovitz et al\[[@B25]\], 2014**                    **Gonzalez et al\[[@B26]\], 2017**                                                 **Kahaleh et al\[[@B27]\], 2018**                         **Rodriguez et al\[[@B28]\], 2017**              **Rodriguez et al\[[@B29]\], 2018**            **Malik et al\[[@B30]\], 2018**           **Jacques et al\[[@B31]\], 2017**                                              **Dacha et al\[[@B32]\], 2017**              **Mekaroonkamol et al\[[@B33]\], 2018**           **Khashab et al\[[@B34]\], 2017**
  --------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------ ---------------------------------------------- ----------------------------------------- ------------------------------------------------------------------------------ -------------------------------------------- ------------------------------------------------- -----------------------------------------------------------------------------------------------------
  *n*                                           7                                                       29                                                                                 33                                                        47                                               100                                            13                                        20                                                                             16                                           30                                                30
  Procedure length (min)                        90-120[1](#T2FN1){ref-type="table-fn"}                  47 ± 22                                                                            77.6 (37-255)                                             41.2 ± 28.5                                      33.8 ± 21.6                                    119 ± 23                                  56.5                                                                           49.7 ± 22.1                                  48.3 ± 16.5                                       72 ± 42
  Length of stay (mean)                         2.3                                                     ---                                                                                5.4 (1-14)                                                1.09 ± 0.6                                       1.3 ± 1.05                                     2.5 ± 1.4 d                               3.75                                                                           2.46                                         2.4 ± 1.0                                         ---
  Pre ABX                                       Yes, IV                                                 Yes, IV                                                                            Gentamicin wash                                           None                                             None                                           Gentamicin wash                           None                                                                           Yes, IV                                      Yes                                               Post-Op
  Site of mucosotomy (cm proximal to pylorus)   5                                                       5                                                                                  5-6                                                       5                                                4                                              5                                         4-5                                                                            5                                            5-7                                               5
  Mucosal entry location                        greater curvature in 31, 2 patients lesser curvature.   Greater curvature 19, anterior wall 9, posterior wall 2                            greater curvature                                         ---                                              95 lesser curvature, 4 greater, 1 posterior    greater curvature                         greater curvature                                                              lesser curvature                             ---                                               ---
  Lift Solution                                 5-10 mL 1: 10000 Epi                                    ---                                                                                5 mL methylene blue and 500 saline mixture                methylene blue[6](#T2FN2){ref-type="table-fn"}   methylene blue                                 Not used                                  glycerol                                                                       5 mL methylene blue and 500 saline mixture   ---                                               saline and 0.25% indigo carmine solution or methylene blue solution[2](#T2FN2){ref-type="table-fn"}
  Size of mucsoal incision (cm)                 1-2                                                     ---                                                                                2                                                         2                                                ---                                            ---                                       ---                                                                            2                                            3-4                                               1.5-2
  Knife Used                                    T Knife                                                 Triangle knife                                                                     Hybrid knife or IT2                                       Triangular knife                                 triangle tip knife                             I-Type Hybrid knife                       T-Type for initial incision, Hybrid knife for tunnel, Hook Knife for myotomy   Hook Knife or I-type knife                   I hybrid knife                                    Triangular tip knife
  Size of myotomy mean (cm)                                                                             2                                                                                  3.34 (2-6)                                                ---                                              ---                                            3.5 ± 0.8                                 ---                                                                            3.94                                         2-3                                               ---
  Upper GI series                               ---                                                     ---                                                                                ---                                                       POD 1                                            POD 1                                          POD 1-2                                   ---                                                                            POD 1                                        POD 1                                             POD 1
  Use of PPI                                    BID PPI for 6 wk                                        BID PPI for 4 wk                                                                   ---                                                       PPI BID for 4 wk w/Sucralfate                    BID PPI and QID sucralfate for at least 2 wk   ---                                       ---                                                                            ---                                          BID for 8 wk                                      
  Antibiotics on discharge                      ---                                                     ---                                                                                ---                                                       ---                                              ---                                            ---                                       ---                                                                            5 d oral Abx                                 ---                                               IV Abx following procedure
  Dietary restrictions                          Clear liquid immediately, pureed/soft diet for 2 wk,    observed for 1 d NPO, then advanced to clears, observed for 5 d and sent home on   Clear liquid diet 2-3 d, advanced to gastroparetic diet   advanced to clears with liquid diet for 2 wk     liquid diet for 2-4 wk                         Clear liquid diet, advance as tolerated   Liquid diet day after procedure                                                advance to liquid after upper GI and ADAT    clear liquid and advanced diet over 4 wk course   liquid diet started then advanced to soft then to gastroparetic diet
  Total of major post operative complications   4/7                                                     5/29                                                                               1/33                                                      0/47                                             10/100                                         1/13                                      3/20                                                                           0/16                                         1                                                 2/30

Time to myotomy;

No specified amount; GCSI: Gastroparesis Cardinal Symptom Index; GES: Gastric Emptying Study; CPGAS: Clinical Patient Grading Assessment Scale; G-POEM: Per-oral endoscopic pyloromyotomy; BID Twice daily; PPI: Proton Pump Inhibitor; ABX: Antibiotics; IV: Intravenous; POD: Post operative day; NPO: *Nil per os*; ADAT: Advance diet as tolerated.

LIMITATIONS
===========

There are several limitations to these published studies. Mainly there is significant heterogeneity between the studies with regards to demographic data, patient selection, pre- and post-operative testing, and in determination and assessment of clinical response. Additionally, the published reports are largely retrospective in nature with no true control groups; moreover, they experienced significant drop out rates in regard to follow up assessment and testing without inclusion of any intention to treat analysis. There was no standard approach towards type or duration of pre-myotomy medications or interventions and no standard approach in determining pre-procedural symptom severity. Furthermore, as highlighted in Table [2](#T2){ref-type="table"}, there was no standardized technique with regards to the G-POEM procedure itself, with significant differences in location of myotomy position, myotomy size, equipment used and post-procedural medications and testing.

WHERE DO WE GO FROM HERE?
=========================

The above heterogeneity highlights a need for validated formalized pre- and post-operative testing, and careful stratification of symptoms. This would allow objective measurement of gastroparesis severity, which could allow subsequent accurate determination of optimal procedural candidates. Additionally, concurrent or peri-operative use of novel assessments of pyloric pressure and distension *via* FLIP\[[@B35]-[@B37]\], classification of gastric contractile patterns *via* electrogastrography\[[@B38]\], or response to previous pyloric-directed therapies including pyloric botulinum toxin injection or pyloric stent placement\[[@B11]-[@B18]\] could prove useful in identifying a subgroup of patients that would be best served by G-POEM. Moreover, identifying and classifying patients based on emerging histopathologic features of gastroparesis such as loss of intestinal cells of Cajal, degree of collagen fibrosis, smooth muscle abnormalities, or alterations in the gastric muscle macrophage population\[[@B39]-[@B42]\] all may prove useful in further stratifying patients into subgroups that may provide further clarity into which patients would best benefit from endoscopic pyloromyotomy.

While the current published literature demonstrates significant optimism regarding the efficacy of G-POEM for the treatment of gastroparesis, gastroparesis itself is a markedly heterogeneous disease entity and caution should be used in interpretation of short term follow-up data in a disease that has demonstrated significant placebo response in the past\[[@B43]\]. Based on this, there is a clear need for a randomized blinded prospective trial, although overall the design of this trial remains unclear. Consideration for G-POEM *vs* sham procedure is ideal but may have ethical and blinding considerations. Alternative options including randomized crossover studies utilizing G-POEM *vs* other pyloric-directed therapies, including botulinum toxin injection, pyloric stenting, or surgical pyloromyotomy, is an attractive option that may help mitigate some of the ethical and blinding concerns. Regardless of the approach, these studies are likely best served *via* multicenter investigation secondary to the total numbers required to power such a study.

Questions including the optimal number of training cases prior to competency also require consideration. Previously published literature in POEM has identified a wide range of conflicting reports for the number of required cases prior to accepted clinical competency, with ranges from 20-100\[[@B21]-[@B44]\], and it is not clear if the learning curve for G-POEM follows a similar pattern to POEM. Other potential procedural issues that require future attention include determination/comparison of the various technical aspects of the procedure (*i.e*., type or location or myotomy) and determination of the optimal timing of G-POEM either sequentially or in combination with other therapeutic modalities for gastroparesis.

Additionally, it is not clear if the ultimate therapeutic efficacy of G-POEM is secondary to pyloric disruption alone or if pyloric disruption results in yet undetermined physiologic alterations. Rao *et al*\[[@B45]\] previously established that fundic distension *via* balloon insufflation led to increases in phasic motor activity within the antrum and duodenum. It is unclear whether similar adaptive changes in the fundus or duodenum are seen following endoscopic pyloromyotomy.

CONCLUSION
==========

Gastroparesis is a chronic disease with significant associated morbidity. G-POEM demonstrates an exciting potential therapeutic addition to a limited armamentarium and may ultimately be a safer option than many of the medical options currently available. However, more investigation is needed to identify optimal candidates, including a standardized approach to pre- and post-operative testing, developing a standard endoscopic approach and further studies into the physiologic effects of G-POEM. Ultimately, we suspect that GPOEM may be an excellent candidate for a subgroup of gastroparesis patients with pyloric dysfunction; however, stan-dardization and data are needed to ensure that this procedure is best positioned to help those patients who may most benefit from pyloric intervention.
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